[Acipimox (Olbetam) as a secondary hypolipemic agent in combined hypertriglyceridemia and hyperlipidemia].

Abstract

32 patients with hypertriglyceridemia, excessive hypertriglyceridemia, and combined hyperlipidemia, were treated with the nicotinic acid derivative acipimox (Olbetam). First line treatment with bezafibrate, or statins in some with combined hyperlipidemia, had failed. In 10 acipimox was discontinued due to side effects or absence of clinical response. The other 22 completed 6 months of treatment with no side effects. Acipimox caused a significant 54% decrease in triglyceride levels, a 23% decrease in total cholesterol, and a 12% increase in HDL-cholesterol. LDL-cholesterol was difficult to calculate because of the high triglyceride levels, so no results are presented. Although acipimox was much better tolerated than nicotinic acid, it also had side effects, but fewer. Acipimox can therefore be used as a second-line drug, mainly in those with combined hyperlipidemia and hypertriglyceridemia.

• Authors: D Yeshurun, H Hamood, N Morad, J Naschitz
• Journal: Harefuah (Harefuah) Vol. 138 Issue 8 Pg. 650-3, 710 (Apr 16 2000) ISSN: 0017-7768 [Print] Israel
• PMID: 10883206 (Publication Type: Clinical Trial, English Abstract, Journal Article)

Chemical References

• Cholesterol, HDL
• Hypolipidemic Agents
• Pyrazines
• Triglycerides
• Cholesterol
• acipimox

Topics

• Adult
• Aged
• Cholesterol (blood)
• Cholesterol, HDL (blood)
• Drug Therapy, Combination
• Female
• Humans
• Hyperlipidemias (blood, complications, drug therapy)
• Hypertriglyceridemia (blood, complications, drug therapy)
• Hypolipidemic Agents (adverse effects, therapeutic use)
• Male
• Middle Aged
• Pyrazines (adverse effects, therapeutic use)
• Triglycerides (blood)